Coya Therapeutics, Inc. COYA

Company Overview

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunomodulatory therapies for neurodegenerative, autoimmune, and metabolic diseases. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on therapies designed to enhance regulatory T cell (Treg) function and reduce chronic inflammation. Its research and development efforts are primarily directed toward diseases characterized by immune dysfunction, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer’s disease, Parkinson’s disease, and other inflammatory conditions.

The company’s primary value drivers are its Treg-focused biologic and cell therapy platforms, including low-dose interleukin-2 (LD IL-2)–based approaches and combination immunotherapies intended to restore immune homeostasis. Coya Therapeutics has positioned itself within a specialized segment of immunology-focused neuroscience by targeting inflammatory pathways increasingly associated with neurodegeneration. Founded in 2020 and headquartered in Houston, Texas, the company became publicly traded on the NASDAQ under the ticker COYA following its initial public offering in 2023. Its evolution has centered on advancing translational immunology research into clinical-stage therapeutic candidates.

Business Operations

Coya Therapeutics operates primarily through a single biotechnology development platform focused on immune modulation and Treg biology. The company generates value through the advancement of proprietary therapeutic candidates, licensing arrangements, collaborative research partnerships, and intellectual property development. Its lead programs include investigational therapies for ALS and neurodegenerative diseases using combinations of LD IL-2 and biologic agents intended to suppress inflammatory signaling while enhancing protective immune responses.

Operations are concentrated in the United States, though the company engages with international clinical research organizations, academic collaborators, and biotechnology partners. Key assets include proprietary know-how related to Treg enhancement, clinical-stage immunotherapy candidates, and associated patents and licensing rights. The company has entered strategic collaborations with organizations including Dr. Reddy’s Laboratories for development and commercialization initiatives related to certain neurodegenerative disease therapies. As a clinical-stage company, revenue generation remains limited relative to commercial-stage pharmaceutical firms, with funding primarily derived from equity financing, partnerships, and research-related agreements.

Strategic Position & Investments

The strategic direction of Coya Therapeutics centers on expanding the therapeutic application of Treg-enhancing technologies across multiple disease indications involving chronic inflammation and immune dysregulation. The company has prioritized clinical advancement of its ALS programs while evaluating broader opportunities in Alzheimer’s disease, Parkinson’s disease, autoimmune disorders, and metabolic inflammation. Its strategy emphasizes combination therapies designed to address multiple inflammatory mechanisms simultaneously, which differentiates its approach from single-target immunotherapies.

A notable strategic initiative includes collaboration and licensing arrangements with Dr. Reddy’s Laboratories, intended to support clinical development and potential commercialization activities. The company also continues to invest in expanding its immunology-focused intellectual property portfolio and translational research capabilities. Emerging areas of interest include neuroinflammation biomarkers, precision immunotherapy, and broader applications of Treg biology in chronic disease management. Public filings and investor disclosures indicate that management views immune restoration as a foundational therapeutic platform with potential relevance across several large unmet-need markets.

Geographic Footprint

Coya Therapeutics is headquartered in Houston, Texas, and its operational activities are primarily concentrated in the United States. The company conducts clinical development activities through collaborations with domestic and international research institutions, contract research organizations, and clinical trial networks. While its direct commercial footprint remains limited due to its clinical-stage status, its research collaborations and licensing activities provide exposure to broader global biopharmaceutical markets.

The company’s strategic relationships, including those involving India-based Dr. Reddy’s Laboratories, contribute to an expanding international profile. Its therapeutic focus targets diseases with substantial global prevalence, positioning the company for potential future international commercialization opportunities if regulatory approvals are achieved. Current public disclosures indicate that North America remains the company’s principal operational and regulatory market.

Leadership & Governance

Coya Therapeutics was co-founded by executives and scientific leaders with backgrounds in biotechnology, immunology, and neurodegenerative disease research. The company’s leadership strategy emphasizes translational science, clinical development discipline, and partnership-driven growth. Management has consistently highlighted the importance of targeting immune dysfunction as a core driver of neurodegenerative disease progression, with a focus on developing therapies supported by biomarker and mechanistic data.

Key executives include:

• Howard H. Berman – Executive Chairman
• Arun Swaminathan – Chief Executive Officer and President
• David Snyder – Chief Medical Officer
• Sujatha Reddy, M.D. – Chief Scientific Officer
• Michael D. Lee – Chief Financial Officer

Corporate governance oversight is provided through the company’s board of directors and public company reporting obligations, including disclosures contained in SEC filings, annual reports, and investor communications. Leadership communications have emphasized disciplined clinical execution, strategic partnerships, and the advancement of immune-modulating therapies for diseases with significant unmet medical need.